Literature DB >> 31074983

Conjugation of Short Peptides to Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Determines M2R Selectivity.

Andrea Pegoli1, David Wifling1, Corinna G Gruber1, Xueke She1, Harald Hübner2, Günther Bernhardt1, Peter Gmeiner2, Max Keller1.   

Abstract

Muscarinic acetylcholine receptors (MRs), comprising five subtypes (M1R-M5R) in humans, exhibit a high degree of structural similarity. Therefore, subtype-selective MR agonists and antagonists are lacking. We present an approach to highly M2R-selective MR antagonists based on the conjugation of di- or tripeptides to M2R-preferring dibenzodiazepinone-type MR antagonists. M2R selectivity was dependent on the peptide sequence and on the type of linker. The introduction of basic amino acids resulted in improved M2R selectivity (e.g., UR-AP148 (48): p Ki (hM2R) of 8.97, ratio of Ki M1R/M2R/M3R/M4R/M5R of 49:1:6500:60:400) compared to reported pyridobenzo- and dibenzodiazepinone-type MR ligands. A supposed dualsteric binding mode of the DIBA-peptide conjugates, such as 48, at MRs was supported by molecular dynamics simulations.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31074983     DOI: 10.1021/acs.jmedchem.8b01967

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Argininamide-type neuropeptide Y Y1 receptor antagonists: the nature of N ω-carbamoyl substituents determines Y1R binding mode and affinity.

Authors:  Jonas Buschmann; Theresa Seiler; Günther Bernhardt; Max Keller; David Wifling
Journal:  RSC Med Chem       Date:  2020-01-20

2.  Differently fluorescence-labelled dibenzodiazepinone-type muscarinic acetylcholine receptor ligands with high M2R affinity.

Authors:  Corinna G Gruber; Andrea Pegoli; Christoph Müller; Lukas Grätz; Xueke She; Max Keller
Journal:  RSC Med Chem       Date:  2020-06-08

3.  Basal Histamine H4 Receptor Activation: Agonist Mimicry by the Diphenylalanine Motif.

Authors:  David Wifling; Christopher Pfleger; Jonas Kaindl; Passainte Ibrahim; Ralf C Kling; Armin Buschauer; Holger Gohlke; Timothy Clark
Journal:  Chemistry       Date:  2019-10-16       Impact factor: 5.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.